The company maintains a conservative capital structure with a debt-to-equity ratio of 0.04 as of 2026Q1, supported by a growing deferred revenue backlog of $305.2 million.
| Total Current Assets | 535.13M | 575.85M | 567.59M | 422.08M | 295.93M | 273.21M | 324.27M | 261.88M |
| Cash & Short-Term Investments | 429.07M | 437.05M | 447.22M | 302.92M | 183.62M | 181.56M | 237.64M | 200.25M |
| Cash Only | 133.69M | 124.46M | 191.66M | 189.52M | 87.64M | 145.97M | 128.71M | 76.55M |
| Short-Term Investments | 295.38M | 312.59M | 255.56M | 113.41M | 95.98M | 35.59M | 108.93M | 123.71M |
| Accounts Receivable | 72.74M | 104.97M | 82.36M | 77.27M | 78.76M | 67.5M | 66.32M | 44.24M |
| Days Sales Outstanding | 68.94 | 80.55 | 74.93 | 86.75 | 106.22 | 100.06 | 124.2 | 93.95 |
| Inventory | 7.53M | 7.6M | 8.94M | 9.94M | 10.18M | 6.51M | 4.75M | 3.96M |
| Days Inventory Outstanding | 37.95 | 36.92 | 52.13 | 68.16 | 73.19 | 55.84 | 45.81 | 40.35 |
| Other Current Assets | 25.8M | 6.59M | 18.18M | 23.06M | 14.77M | 7.88M | 11.24M | 8.86M |
| Total Non-Current Assets | 417.15M | 363M | 122.97M | 123.86M | 107.36M | 66.57M | 40.12M | 18.36M |
| Property, Plant & Equipment | 39.55M | 38.52M | 27.6M | 30.16M | 32.91M | 16.76M | 16.11M | 14.82M |
| Fixed Asset Turnover | 12.87x | 12.35x | 14.54x | 10.78x | 8.22x | 14.70x | 12.10x | 11.59x |
| Goodwill | 119.56M | 119.56M | 28.71M | 26.83M | 26.83M | 26.83M | 9.46M | 0 |
| Intangible Assets | 127.97M | 81.47M | 11.31M | 10.59M | 11.25M | 11.23M | 6.61M | 0 |
| Long-Term Investments | 358.69M | 97.96M | 36.6M | 28.86M | 22.13M | 0 | 0 | 0 |
| Other Non-Current Assets | 12.82M | 25.5M | 7.68M | 12.89M | 1.73M | 1.96M | 565K | 447K |
| Total Assets | 952.29M | 938.85M | 690.57M | 532.88M | 403.29M | 339.78M | 364.39M | 280.24M |
| Asset Turnover | 0.57x | 0.51x | 0.58x | 0.61x | 0.67x | 0.72x | 0.53x | 0.61x |
| Asset Growth % | 144.16% | 35.95% | 29.59% | 32.13% | 18.69% | -6.75% | 30.03% | - |
| Total Current Liabilities | 350.21M | 369.66M | 295.5M | 253.82M | 207.78M | 186.57M | 159.38M | 99.16M |
| Accounts Payable | 10.87M | 16.83M | 11.08M | 8.28M | 4.61M | 9.55M | 4.73M | 5.36M |
| Days Payables Outstanding | 56.3 | 81.74 | 64.59 | 56.79 | 33.17 | 81.87 | 45.55 | 54.61 |
| Short-Term Debt | 4.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 721.95M | 0 | 217.64M | 196.59M | 153.34M | 123.68M | 106.1M | 69.79M |
| Other Current Liabilities | 79.65M | 348.83M | 0 | 9.04M | 0 | 0 | 0 | 0 |
| Current Ratio | 1.53x | 1.56x | 1.92x | 1.66x | 1.42x | 1.46x | 2.03x | 2.64x |
| Quick Ratio | 1.51x | 1.54x | 1.89x | 1.62x | 1.38x | 1.43x | 2.00x | 2.60x |
| Cash Conversion Cycle | 50.59 | 35.73 | 62.46 | 98.12 | 146.24 | 74.03 | 124.46 | 79.69 |
| Total Non-Current Liabilities | 91.53M | 84.88M | 59.05M | 244.85M | 121.65M | 226.56M | 141.2M | 122.25M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 72.8M | 18.67M | 6.84M | 9.16M | 10.35M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 23.18M | 66.2M | 6.95M | 188.59M | 69.13M | 190.13M | 107.76M | 103.32M |
| Total Liabilities | 441.75M | 454.53M | 354.55M | 498.67M | 329.43M | 413.13M | 300.58M | 221.41M |
| Total Debt | 22.8M | 22.67M | 10.97M | 14.13M | 15.36M | 0 | 0 | 0 |
| Net Debt | -110.88M | -101.79M | -180.69M | -175.39M | -72.29M | -145.97M | -128.71M | -76.55M |
| Debt / Equity | 0.04x | 0.05x | 0.03x | 0.41x | 0.21x | - | - | - |
| Debt / EBITDA | 0.29x | 0.29x | 0.16x | 0.33x | 1.50x | - | - | - |
| Net Debt / EBITDA | -1.39x | -1.30x | -2.68x | -4.06x | -7.06x | -7.01x | -8.53x | -29.91x |
| Interest Coverage | - | - | -0.79x | - | 811.47x | 538.94x | 8.01x | 4.39x |
| Total Equity | 510.54M | 484.32M | 336.02M | 34.21M | 73.86M | -73.35M | 63.8M | 58.83M |
| Equity Growth % | 1251.65% | 44.13% | 882.17% | -53.68% | 200.71% | -214.96% | 8.46% | - |
| Book Value per Share | 2.03 | 1.94 | 1.60 | 0.18 | 0.38 | -0.45 | 0.34 | 0.31 |
| Total Shareholders' Equity | 510.54M | 484.32M | 336.02M | 34.21M | 73.86M | -73.35M | 63.8M | 58.83M |
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -75.6M | -86.54M | -164.86M | 118.14M | 199.24M | 78.44M | 28.34M | 32.56M |
| Treasury Stock | -85K | -85K | -85K | -85K | -85K | -85K | -85K | 0 |
| Accumulated OCI | 992K | 2.22M | 2.09M | 1.05M | 331K | 1.37M | 1.32M | 804K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Geopolitical and regulatory exposure
According to recent financial filings, Cellebrite has successfully transitioned from a negative equity position of $40.2 million in 2024Q2 to a robust $510.5 million in 2026Q1, signaling a significant improvement in the company's underlying financial health as it scales its subscription-based digital intelligence platform.
The rapid accumulation of equity suggests that the company is successfully retaining earnings and managing its capital structure more effectively than in previous periods. This trajectory indicates that the business model is maturing, moving away from the volatility associated with its earlier public market entry.
As reported in quarterly balance sheets, Cellebrite maintains a conservative capital structure with a debt-to-equity ratio of just 0.04 as of 2026Q1, reflecting a strategic preference for internal funding over external borrowing to support its ongoing research and development initiatives.
The negligible debt load provides the company with significant financial optionality, allowing it to navigate potential geopolitical or market-driven disruptions without the burden of interest obligations. This low-leverage profile appears to be a deliberate choice to maintain agility in a sector where R&D requirements are non-discretionary.
Based on the latest reported figures, Cellebrite holds $133.7 million in cash and maintains a current ratio of 1.53, which suggests the company possesses an adequate liquidity buffer to meet its short-term obligations while continuing to invest in its proprietary decryption and forensic software suite.
While the cash position has fluctuated significantly over the last ten quarters, the current ratio remains comfortably above parity, indicating that the company is not overly reliant on external financing for day-to-day operations. Investors should monitor whether this liquidity remains stable as the company pursues further M&A opportunities.
As indicated by the company's 2026Q1 balance sheet, deferred revenue has climbed to $305.2 million, providing a clear window into the firm's growing subscription-based backlog and suggesting that the transition to a recurring revenue model is gaining significant traction among its global law enforcement customer base.
This substantial deferred revenue balance serves as a leading indicator of future top-line stability, effectively de-risking the revenue stream against short-term procurement volatility. The consistent growth in this metric implies that the company's digital intelligence platform is becoming increasingly embedded in the evidentiary workflows of its clients.
Based on the provided data, goodwill has increased from $26.8 million in 2024Q2 to $119.6 million in 2026Q1, which may indicate that recent acquisitions are playing a larger role in the company's growth strategy than organic development alone, potentially introducing future impairment risks.
The rising goodwill balance suggests that Cellebrite is paying premiums to consolidate the forensic software market, which warrants careful monitoring to ensure these assets continue to generate expected returns. If the integration of these acquired technologies fails to meet performance targets, the company could face non-cash write-downs that would impact its equity base.
Quick answers to the most common questions about buying CLBT stock.
As of 2025, Cellebrite DI Ltd. (CLBT) had total assets of $938.9M including $575.9M in current assets.
Cellebrite DI Ltd. (CLBT) carries total debt of $22.7M, offset by $437.1M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Cellebrite DI Ltd. (CLBT) has total shareholders' equity (book value) of $484.3M ($1.94 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Cellebrite DI Ltd. (CLBT) reported a current ratio of 1.56x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.